EGFR and non-small cell lung carcinoma: Nevertheless, the clinical efficacy of these agents against T790M-associated NSCLC was constrained due to their ability to inhibit wild-type EGFR, leading to toxicity and a limited therapeutic range [[20], [21], [22]].